Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1997 1
2006 1
2007 1
2008 1
2010 1
2011 3
2012 5
2013 6
2014 8
2015 28
2016 16
2017 30
2018 34
2019 57
2020 63
2021 80
2022 50
2023 15
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 28561918

349 results

Results by year

Filters applied: . Clear all
Page 1
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K, Kudo M, Kawazoe S, Osaki Y, Ikeda M, Okusaka T, Tamai T, Suzuki T, Hisai T, Hayato S, Okita K, Kumada H. Ikeda K, et al. J Gastroenterol. 2017 Apr;52(4):512-519. doi: 10.1007/s00535-016-1263-4. Epub 2016 Oct 4. J Gastroenterol. 2017. PMID: 27704266 Free PMC article. Clinical Trial.
Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
Takahashi A, Moriguchi M, Seko Y, Ishikawa H, Yo T, Kimura H, Fujii H, Shima T, Mitsumoto Y, Ishiba H, Takashima H, Nagao Y, Jo M, Arai M, Hara T, Okajima A, Muramatsu A, Morita A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Itoh Y. Takahashi A, et al. Anticancer Res. 2019 Sep;39(9):5149-5156. doi: 10.21873/anticanres.13710. Anticancer Res. 2019. PMID: 31519627
Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.
Kirino S, Tsuchiya K, Kurosaki M, Kaneko S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Okada M, Wang W, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Izumi N. Kirino S, et al. PLoS One. 2020 Apr 20;15(4):e0231828. doi: 10.1371/journal.pone.0231828. eCollection 2020. PLoS One. 2020. PMID: 32310967 Free PMC article.
349 results